- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.04. | Sanofi stays course amid tariff turmoil | ||
| 24.04. | Versant startup Granite debuts with $100M and two immune drugs | ||
| 24.04. | Etiome, a new Flagship startup, looks to catch disease before it strikes | ||
| 23.04. | [Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care | ||
| 23.04. | German antibody maker Veraxa Biotech valued at $1.6B in blank-check merger | ||
| 23.04. | Bristol Myers' prized schizophrenia drug stumbles in testing | ||
| 23.04. | Roche looks to a Flagship startup in search of new immune drugs | ||
| 22.04. | Roche, answering tariff threat, pledges $50B to US drug production | ||
| 22.04. | Former Neumora CEO to lead Galapagos spinout | ||
| 22.04. | The Trump administration is remaking HHS. Track the changes here. | ||
| 22.04. | Arkansas passes law banning PBMs from owning pharmacies | ||
| 21.04. | Novo says it's submitted obesity pill for FDA approval | ||
| 21.04. | Enhertu combo tops standard drugs in first-line HER2 breast cancer | ||
| 18.04. | An investment fund sets out to free biotech's 'trapped capital' | ||
| 18.04. | Sanofi, Regeneron win FDA nod for Dupixent in chronic hives | ||
| 18.04. | Makary seeks to limit industry's role in FDA advisory panels | ||
| 18.04. | GSK prepares to relaunch Blenrep; Activists challenge another 'zombie' biotech | ||
| 18.04. | FDA cuts outlined in draft HHS budget | ||
| 17.04. | Lilly's obesity pill scores in large diabetes trial | ||
| 17.04. | Sanofi licenses immune disease drugs from startup Earendil | ||
| 17.04. | A judge blocked the FDA's plan to regulate lab developed tests. What now? | ||
| 17.04. | CDC panel backs broader use of RSV shots | ||
| 16.04. | Bluebird says Ayrmid missed deadline for rival takeover bid | ||
| 16.04. | New research kindles excitement around stem cell therapies for Parkinson's | ||
| 16.04. | Trump signals plan to address 'pill penalty' of drug pricing law |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .